<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Actual problems in dentistry</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Actual problems in dentistry</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Проблемы стоматологии</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2077-7566</issn>
   <issn publication-format="online">2412-9461</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">55052</article-id>
   <article-id pub-id-type="doi">10.18481/2077-7566-2022-18-3-65-70</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>ЛЕКЦИИ / ЛИТЕРАТУРНЫЕ ОБЗОРЫ</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>LITERATURE REVIEW</subject>
    </subj-group>
    <subj-group>
     <subject>ЛЕКЦИИ / ЛИТЕРАТУРНЫЕ ОБЗОРЫ</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">OSTEOMODIFYING AGENTS AND BIPHOSPHONATE OSTEONECROSIS OF THE JAW: FOREIGN STUDIES</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>ОСТЕОМОДИФИЦИРУЮЩИЕ АГЕНТЫ И БИФОСФОНАТНЫЙ ОСТЕОНЕКРОЗ ЧЕЛЮСТЕЙ: ЗАРУБЕЖНЫЕ ИССЛЕДОВАНИЯ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8381-2535</contrib-id>
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Шелегова</surname>
       <given-names>Ирина Георгиевна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Shelegova</surname>
       <given-names>Irina Georgievna</given-names>
      </name>
     </name-alternatives>
     <email>irina-stomat@rambler.ru</email>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Нуриева</surname>
       <given-names>Наталья Сергеевна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Nurieva</surname>
       <given-names>Natal'ya Sergeevna</given-names>
      </name>
     </name-alternatives>
     <email>natakipa@mail.ru</email>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">ООО &quot;Центральная стоматология&quot;</institution>
     <city>Челябинск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">ООО &quot;Центральная стоматология&quot;</institution>
     <city>Челябинск</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">Южно-Уральский государственный медицинский университет</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Южно-Уральский государственный медицинский университет</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2022-11-23T21:53:19+03:00">
    <day>23</day>
    <month>11</month>
    <year>2022</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-11-23T21:53:19+03:00">
    <day>23</day>
    <month>11</month>
    <year>2022</year>
   </pub-date>
   <volume>18</volume>
   <issue>3</issue>
   <fpage>65</fpage>
   <lpage>70</lpage>
   <history>
    <date date-type="received" iso-8601-date="2022-11-12T00:00:00+03:00">
     <day>12</day>
     <month>11</month>
     <year>2022</year>
    </date>
   </history>
   <self-uri xlink:href="https://dental-press.ru/en/nauka/article/55052/view">https://dental-press.ru/en/nauka/article/55052/view</self-uri>
   <abstract xml:lang="ru">
    <p>Предмет. Актуальность данного обзора связана с увеличением числа пациентов, принимающих остеомодифицирующие агенты. Они используются при лечении метастазов в кости злокачественных опухолей и при остеопорозе. Известно серьезное осложнение, связанное с приемом остеомодифицирующих агентов — бифосфонатов: бифосфонатный остеонекроз челюстей; также появляются данные о развитии остеонекроза челюстей при приеме деносумаба. Однако патогенез данного осложнения полностью не изучен. Изучение этиологических факторов и патогенетических механизмов развития остеонекроза челюстей, связанного с приемом остеомодифицирующих агентов, позволит предотвратить его на ранней стадии и улучшить качество жизни пациентов. &#13;
Цель — анализ зарубежных исследований о влиянии на организм человека остеомодифицирующих агентов и о связанном с ними остеонекрозе челюстей.&#13;
Методология. Обзор литературы выполнен на основании анализа опубликованных исследований. По ключевым словам на электронном ресурсе журнала «Nature» подобраны зарубежные научные работы, в которых приводятся результаты исследований влияния на организм человека остеомодифицирующих агентов и рассматриваются связанные с ними случаи остеонекроза челюстей.&#13;
Результаты. Остеомодифицирующие агенты увеличивают плотность костной ткани посредством нескольких механизмов. Однако некоторые остеомодифицирующие агенты повышают риск развития атипичных переломов бедренных костей, предплечий, позвонков, увеличивают частоту возникновения остеонекроза челюстей и некоторых видов рака. Продолжаются исследования факторов риска развития данных осложнений у пациентов, принимающих остеомодифицирующие агенты.&#13;
Выводы. Остеомодифицирующие агенты широко применяются в онкологии и профилактике возрастных изменений костной системы человека. Во всем мире ведутся исследования терапевтических эффектов и осложнений терапии остеомодифицирующими агентами.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Subject. The relevance of this review is related to the increasing number of patients taking osteomodifying agents. Osteomodifying agents are used in the treatment of bone metastases of malignant tumors and osteoporosis. A serious complication associated with the use of osteomodifying agents – bisphosphonates – is bisphosphonate osteonecrosis of the jaw. There are also data on the development of osteonecrosis of the jaw when taking denosumab. However, the pathogenesis of this complication is not fully understood. Study of etiological factors and pathogenetic mechanisms of jaw osteonecrosis development, associated with taking osteomodifying agents will allow to prevent it at early stages and improve quality of life of patients.&#13;
Objectives – analysis of foreign studies on the impact of osteomodifying agents on the human body and associated osteonecrosis of the jaws.&#13;
Methodology. The literature review was carried out on the basis of the analysis of the published studies. Using the key words in the electronic resource of the journal &quot;Nature&quot; the foreign scientific studies with the results of the research on the influence of the osteomodifying agents on the human body and the cases of osteonecrosis of the jaws associated with them were selected.&#13;
Results. OMAs increase bone density through several mechanisms. However, some osteomodifying agents increase the risk of atypical fractures of the femur, forearms, and vertebrae, and increase the incidence of osteonecrosis of the jaw and some cancers. Research continues on risk factors for these complications in patients taking osteomodifying agents.&#13;
Conclusion. Osteomodifying agents are widely used in oncology and prevention of age-related changes in the human bone system. Therapeutic effects and complications of therapy with osteomodifying agents are studied worldwide.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>остеомодифицирующие агенты</kwd>
    <kwd>бифосфонаты</kwd>
    <kwd>костные метастазы</kwd>
    <kwd>остеопороз</kwd>
    <kwd>остеонекроз челюстей</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>osteomodifying agents</kwd>
    <kwd>bisphosphonates</kwd>
    <kwd>bone metastases</kwd>
    <kwd>osteoporosis</kwd>
    <kwd>osteonecrosis of the jaw</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Cassinello Espinosa J., González Del Alba Baamonde A., Rivera Herrero F., Holgado Martín E. SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for the treatment of bone metastases from solid tumours // Clin Transl Oncol. - 2012;14(7):505-511. doi: 10.1007/s12094-012-0832-0.</mixed-citation>
     <mixed-citation xml:lang="en">Cassinello Espinosa J., González Del Alba Baamonde A., Rivera Herrero F., Holgado Martín E. SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for the treatment of bone metastases from solid tumours // Clin Transl Oncol. - 2012;14(7):505-511. doi: 10.1007/s12094-012-0832-0.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Yarom N. et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline // J. Clin. Oncol. - 2019;37:2270-2290. doi: 10.1200/JCO.19.01186.</mixed-citation>
     <mixed-citation xml:lang="en">Yarom N. et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline // J. Clin. Oncol. - 2019;37:2270-2290. doi: 10.1200/JCO.19.01186.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Yang X., Xu X., Chen J. et al. Zoledronic acid regulates the synthesis and secretion of IL-1β through Histone methylation in macrophages // Cell Death Discov. - 2020;6:47. doi:10.1038/s41420-020-0273-4</mixed-citation>
     <mixed-citation xml:lang="en">Yang X., Xu X., Chen J. et al. Zoledronic acid regulates the synthesis and secretion of IL-1β through Histone methylation in macrophages // Cell Death Discov. - 2020;6:47. doi:10.1038/s41420-020-0273-4</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Hughes D.E., MacDonald B.R., Russell R.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow // J. Clin. Investig. - 1989;83:1930-1935. doi: 10.1172/JCI114100.</mixed-citation>
     <mixed-citation xml:lang="en">Hughes D.E., MacDonald B.R., Russell R.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow // J. Clin. Investig. - 1989;83:1930-1935. doi: 10.1172/JCI114100.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Hughes D.E. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo // J. Bone Miner. Res. - 1995;10:1478-1487.  doi: 10.1002/jbmr.5650101008.</mixed-citation>
     <mixed-citation xml:lang="en">Hughes D.E. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo // J. Bone Miner. Res. - 1995;10:1478-1487.  doi: 10.1002/jbmr.5650101008.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nuti R., Brandi M.L., Checchia G., Di Munno O., Dominguez L., Falaschi P., Fiore C.E., Iolascon G., Maggi S., Michieli R., Migliaccio S., Minisola S., Rossini M., Sessa G., Tarantino U., Toselli A., Isaia G.C. Guidelines for the management of osteoporosis and fragility fractures // Intern Emerg Med.  - 2019;14(1):85-102. DOI:10.1007 / s11739-018-1874-2</mixed-citation>
     <mixed-citation xml:lang="en">Nuti R., Brandi M.L., Checchia G., Di Munno O., Dominguez L., Falaschi P., Fiore C.E., Iolascon G., Maggi S., Michieli R., Migliaccio S., Minisola S., Rossini M., Sessa G., Tarantino U., Toselli A., Isaia G.C. Guidelines for the management of osteoporosis and fragility fractures // Intern Emerg Med.  - 2019;14(1):85-102. DOI:10.1007 / s11739-018-1874-2</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kim Y., Tian Y., Yang J. et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis // Sci Rep. - 2020;10:11115. doi:10.1038/s41598-020-68037-8</mixed-citation>
     <mixed-citation xml:lang="en">Kim Y., Tian Y., Yang J. et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis // Sci Rep. - 2020;10:11115. doi:10.1038/s41598-020-68037-8</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Estell E.G., Rosen C.J. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis // Nat Rev Endocrinol. - 2021;17:31-46. doi:10.1038/s41574-020-00426-5</mixed-citation>
     <mixed-citation xml:lang="en">Estell E.G., Rosen C.J. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis // Nat Rev Endocrinol. - 2021;17:31-46. doi:10.1038/s41574-020-00426-5</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kim J., Jang S.B., Kim S.W., Oh J.K., Kim T.H. Clinical effect of early bisphosphonate treatment for pyogenic vertebral osteomyelitis with osteoporosis: An analysis by the Cox proportional hazard model // Spine J. - 2019;19(3):418-429.  DOI: 10.1016 / j.spinee.2018.08.014.</mixed-citation>
     <mixed-citation xml:lang="en">Kim J., Jang S.B., Kim S.W., Oh J.K., Kim T.H. Clinical effect of early bisphosphonate treatment for pyogenic vertebral osteomyelitis with osteoporosis: An analysis by the Cox proportional hazard model // Spine J. - 2019;19(3):418-429.  DOI: 10.1016 / j.spinee.2018.08.014.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Tanner C.M., Cummings S.R., Schwarzschild M.A. et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism // Parkinsons Dis. - 2021;7:16. Doi:10.1038/s41531-021-00162-1</mixed-citation>
     <mixed-citation xml:lang="en">Tanner C.M., Cummings S.R., Schwarzschild M.A. et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism // Parkinsons Dis. - 2021;7:16. Doi:10.1038/s41531-021-00162-1</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Soo Min Cha, Hyun Dae Shin. Risk factors for atypical forearm fractures associated with bisphosphonate usage // Injury. - 2021;52;6:1423-1428. doi:10.1016/j.injury.2020.10.087.</mixed-citation>
     <mixed-citation xml:lang="en">Soo Min Cha, Hyun Dae Shin. Risk factors for atypical forearm fractures associated with bisphosphonate usage // Injury. - 2021;52;6:1423-1428. doi:10.1016/j.injury.2020.10.087.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Li Y.Y., Gao LJ., Zhang Y.X. et al. Bisphosphonates and risk of cancers: a systematic review and meta-analysis // Br J Cancer. - 2020;123:1570-1581. doi:10.1038/s41416-020-01043-9</mixed-citation>
     <mixed-citation xml:lang="en">Li Y.Y., Gao LJ., Zhang Y.X. et al. Bisphosphonates and risk of cancers: a systematic review and meta-analysis // Br J Cancer. - 2020;123:1570-1581. doi:10.1038/s41416-020-01043-9</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Tesfamariam Y., Jakob T., Wöckel A., Adams A., Weigl A., Monsef I., Kuhr K., Skoetz N. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis // Critical Reviews in Oncology/Hematology. - 2019;137:1-8. Doi:10.1016/j.critrevonc.2019.02.004.</mixed-citation>
     <mixed-citation xml:lang="en">Tesfamariam Y., Jakob T., Wöckel A., Adams A., Weigl A., Monsef I., Kuhr K., Skoetz N. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis // Critical Reviews in Oncology/Hematology. - 2019;137:1-8. Doi:10.1016/j.critrevonc.2019.02.004.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Yuan Y., Song J.X., Zhang M.N. et al. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma // Sci Rep. - 2020;10:15497. doi:10.1038/s41598-020-72552-z</mixed-citation>
     <mixed-citation xml:lang="en">Yuan Y., Song J.X., Zhang M.N. et al. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma // Sci Rep. - 2020;10:15497. doi:10.1038/s41598-020-72552-z</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Jiang Z., Li J., Chen S. et al. Zoledronate and SPIO dual-targeting nanoparticles loaded with ICG for photothermal therapy of breast cancer tibial metastasis // Sci Rep. - 2020;10:13675. doi:10.1038/s41598-020-70659-x</mixed-citation>
     <mixed-citation xml:lang="en">Jiang Z., Li J., Chen S. et al. Zoledronate and SPIO dual-targeting nanoparticles loaded with ICG for photothermal therapy of breast cancer tibial metastasis // Sci Rep. - 2020;10:13675. doi:10.1038/s41598-020-70659-x</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ashrafi M., Ghalichi F., Mirzakouchaki B. et al. On the effect of antiresorptive drugs on the bone remodeling of the mandible after dental implantation: a mathematical model // Sci Rep. - 2021;11:2792. doi:10.1038/s41598-021-82502-y</mixed-citation>
     <mixed-citation xml:lang="en">Ashrafi M., Ghalichi F., Mirzakouchaki B. et al. On the effect of antiresorptive drugs on the bone remodeling of the mandible after dental implantation: a mathematical model // Sci Rep. - 2021;11:2792. doi:10.1038/s41598-021-82502-y</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">de Sousa F.R.N., de Sousa Ferreira V.C., da Silva Martins C. et al. The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats // Sci Rep. - 2021;11:7672. doi:10.1038/s41598-021-87375-9</mixed-citation>
     <mixed-citation xml:lang="en">de Sousa F.R.N., de Sousa Ferreira V.C., da Silva Martins C. et al. The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats // Sci Rep. - 2021;11:7672. doi:10.1038/s41598-021-87375-9</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B18">
    <label>18.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kim J.Y., Jang H.W., Kim J.I. et al. Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats // Sci Rep. - 2021;11:54. Doi:10.1038/s41598-020-79787-w</mixed-citation>
     <mixed-citation xml:lang="en">Kim J.Y., Jang H.W., Kim J.I. et al. Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats // Sci Rep. - 2021;11:54. Doi:10.1038/s41598-020-79787-w</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B19">
    <label>19.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kanwar N., Bakr M., Meer M. et al. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature // Br Dent J. - 2020;228:886-892. doi:10.1038/s41415-020-1642-3</mixed-citation>
     <mixed-citation xml:lang="en">Kanwar N., Bakr M., Meer M. et al. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature // Br Dent J. - 2020;228:886-892. doi:10.1038/s41415-020-1642-3</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B20">
    <label>20.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chadwick J.W., Tenenbaum H.C., Sun CX. et al. The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst // Sci Rep. - 2020;10:8309. doi:10.1038/s41598-020-75272-6</mixed-citation>
     <mixed-citation xml:lang="en">Chadwick J.W., Tenenbaum H.C., Sun CX. et al. The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst // Sci Rep. - 2020;10:8309. doi:10.1038/s41598-020-75272-6</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B21">
    <label>21.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Otto S., Pautke C., Van den Wyngaert T., Niepel D., Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases // Cancer Treat. Rev. - 2018;69:177-187. doi: 10.1016/j.oooo.2018.09.008.</mixed-citation>
     <mixed-citation xml:lang="en">Otto S., Pautke C., Van den Wyngaert T., Niepel D., Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases // Cancer Treat. Rev. - 2018;69:177-187. doi: 10.1016/j.oooo.2018.09.008.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B22">
    <label>22.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Fung P. et al. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study // Oral Dis. - 2017;23:477-483. doi:10.1111/odi.12632 .</mixed-citation>
     <mixed-citation xml:lang="en">Fung P. et al. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study // Oral Dis. - 2017;23:477-483. doi:10.1111/odi.12632 .</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B23">
    <label>23.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Jung S.M., Han S., Kwon H.Y. Dose-intensity of bisphosphonates and the risk of osteonecrosis of the jaw in osteoporosis patients // Front. Pharmacol. - 2018. doi:10.3389/fphar.2018.00796 .</mixed-citation>
     <mixed-citation xml:lang="en">Jung S.M., Han S., Kwon H.Y. Dose-intensity of bisphosphonates and the risk of osteonecrosis of the jaw in osteoporosis patients // Front. Pharmacol. - 2018. doi:10.3389/fphar.2018.00796 .</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B24">
    <label>24.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sankar P.S. et al. Osteonecrosis of the jaw among patients receiving antiresorptive medication: a 4-year retrospective study at a Tertiary Cancer Center, Kerala India // Contemp. Clin. Dent. - 2018;9:35-40. doi:10.4103/ccd.ccd_696_17.</mixed-citation>
     <mixed-citation xml:lang="en">Sankar P.S. et al. Osteonecrosis of the jaw among patients receiving antiresorptive medication: a 4-year retrospective study at a Tertiary Cancer Center, Kerala India // Contemp. Clin. Dent. - 2018;9:35-40. doi:10.4103/ccd.ccd_696_17.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B25">
    <label>25.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kuo P.I., Lin T.M., Chang Y.S. et al. Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw // Sci Rep. - 2021;11:1612. Doi:10.1038/s41598-020-80622-5</mixed-citation>
     <mixed-citation xml:lang="en">Kuo P.I., Lin T.M., Chang Y.S. et al. Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw // Sci Rep. - 2021;11:1612. Doi:10.1038/s41598-020-80622-5</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B26">
    <label>26.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">De Oliveira L.R., Marcelo Ivander Andrade Wanderley et. al. Atypical presentation of MRONJ in a patient with iron-deficiency anemia // Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. - 2020;129;1;e36. https://doi.org/10.1016/j.oooo.2019.06.105.</mixed-citation>
     <mixed-citation xml:lang="en">De Oliveira L.R., Marcelo Ivander Andrade Wanderley et. al. Atypical presentation of MRONJ in a patient with iron-deficiency anemia // Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. - 2020;129;1;e36. https://doi.org/10.1016/j.oooo.2019.06.105.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B27">
    <label>27.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Pichardo S.E.C., J.G. van der Hee, Fiocco M., Appelman-Dijkstra N.M, van Merkesteyn J.P.R. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ) // British Journal of Oral and Maxillofacial Surgery. - 2020;58;7:771-776. doi:10.1016/j.bjoms.2020.03.022</mixed-citation>
     <mixed-citation xml:lang="en">Pichardo S.E.C., J.G. van der Hee, Fiocco M., Appelman-Dijkstra N.M, van Merkesteyn J.P.R. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ) // British Journal of Oral and Maxillofacial Surgery. - 2020;58;7:771-776. doi:10.1016/j.bjoms.2020.03.022</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B28">
    <label>28.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bernardi S., Di Girolamo M., Necozione S., Continenza M.A., Cutilli T. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience // Musculoskelet Surg. - 2019;103(1):47-53. DOI:10.1007 / s12306-018-0548-6</mixed-citation>
     <mixed-citation xml:lang="en">Bernardi S., Di Girolamo M., Necozione S., Continenza M.A., Cutilli T. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience // Musculoskelet Surg. - 2019;103(1):47-53. DOI:10.1007 / s12306-018-0548-6</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B29">
    <label>29.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Eliyas S., Porter R. An impossible choice: MRONJ vs ORN? The difficulties of the decision-making process for head and neck cancer patients on long-term anti-angiogenic medication // Br Dent J. - 2020;229:587-590. doi:10.1038/s41415-020-2276-1</mixed-citation>
     <mixed-citation xml:lang="en">Eliyas S., Porter R. An impossible choice: MRONJ vs ORN? The difficulties of the decision-making process for head and neck cancer patients on long-term anti-angiogenic medication // Br Dent J. - 2020;229:587-590. doi:10.1038/s41415-020-2276-1</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B30">
    <label>30.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ganesan K., Bansal P., Goyal A. et al. Bisphosphonate. Treasure Island (FL) : StatPearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK470248/</mixed-citation>
     <mixed-citation xml:lang="en">Ganesan K., Bansal P., Goyal A. et al. Bisphosphonate. Treasure Island (FL) : StatPearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK470248/</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B31">
    <label>31.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Garcia F., Assuncao N., Siqueira J.M., Pinto C.A., Alves F., Lopes R.N., Rocha A.C. Association of different approaches for an extensive case of osteonecrosis of the jaw // Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. - 2020;129;1:е38. https://doi.org/10.1016/j.oooo.2019.06.114</mixed-citation>
     <mixed-citation xml:lang="en">Garcia F., Assuncao N., Siqueira J.M., Pinto C.A., Alves F., Lopes R.N., Rocha A.C. Association of different approaches for an extensive case of osteonecrosis of the jaw // Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. - 2020;129;1:e38. https://doi.org/10.1016/j.oooo.2019.06.114</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
